Sodium nitroprusside for advanced heart failure. A metanalysis of literature data

• Published in: Vascular pharmacology Vol. 148; p. 107140
• Main Authors: Ghio, S., Mandurino-Mirizzi, A., La Rovere, M.T., Traversi, E., Lombardi, C., Scelsi, L., Senni, M., Iacovoni, A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-02-2023
• Subjects: Advanced heart failure; Heart Failure - diagnosis; Heart Failure - drug therapy; Humans; Nitroprusside - adverse effects; Prognosis; Sodium nitroprusside; Survival; Sodium nitroprusside; Survival; Advanced heart failure
• ISSN: 1537-1891; 1879-3649
• DOI: 10.1016/j.vph.2022.107140

Advanced heart failure (HF) is associated with a very poor prognosis and places a big burden on health-care services. The gold standard treatment, i.e. long-term mechanical circulatory support or heart transplantation, is precluded in many patients but observational studies suggest that the use of SNP might be associated with favourable long-term clinical outcomes. We performed a metanalysis of published studies that compared sodium nitroprusside (SNP) with optimal medical therapy to examine the safety and efficacy of SNP as part of the treatment regimen of patients hospitalized for advanced heart failure (HF).
We searched PUBMED, EMBASE and WEB OF SCIENCE for studies that compared SNP with optimal medical therapy in advanced HF on July 2022. After screening 700 full-text articles, data from two original articles were included in a combined analysis. The analysis demonstrated a 66% reduction in the odds of death in advanced HF patients treated with SNP.
The results show the potential importance of the inclusion of SNP in the treatment regimen of patients hospitalized because of advanced HF and underlines that controlled, randomized studies are still required in this condition.